The FDA has granted Breakthrough Therapy designation to daraxonrasib, the RAS-blocking pill sold as Rasonque, for use with standard chemotherapy in people with metastatic pancreatic cancer who have not yet been treated. Developer Revolution Medicines announced the designation on Sept. 14, less than three weeks after the drug's first FDA approval.
The designation covers daraxonrasib combined with gemcitabine and nab-paclitaxel, a chemotherapy regimen widely used for this cancer. Using that combination first would move the drug to the start of care instead of reserving it for patients who have already been treated.
For newly diagnosed patients and their families, the news is meaningful but limited, because the combination is still investigational. A large ongoing trial will help determine whether it works better than chemotherapy alone.
A Designation, Not an Approval
Breakthrough Therapy designation is meant to speed the development and review of drugs for serious conditions when preliminary clinical evidence suggests a substantial improvement over available therapy on at least one clinically significant endpoint. It brings closer FDA guidance and can support a faster review. It does not mean the agency has found the treatment safe and effective for this use, and it does not guarantee approval.
Today, daraxonrasib is FDA-approved only for the use described in the agency's approval notice for previously treated metastatic disease. The FDA cleared it on Aug. 26 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
That approval rested on the phase 3 RASolute 302 trial, which randomly assigned 500 patients. Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy, and median progression-free survival was 7.2 versus 3.6 months, OncoDaily reported. The study was funded by Revolution Medicines.
"This Breakthrough Therapy Designation underscores the significant unmet need among patients with previously untreated metastatic pancreatic adenocarcinoma," said Dr. Alan Sandler, the company's chief development officer. The company says this is the third Breakthrough Therapy designation for daraxonrasib.
Early Results from 40 Patients
The first-line designation is based on the phase 1/2 RMC-GI-102 study, an open-label trial without a comparison group. In previously reported results from 40 patients with untreated, RAS-mutant metastatic pancreatic cancer, the combination produced a confirmed response rate of 58%, a measure of meaningful tumor shrinkage, including one complete response.
At a Dec. 1, 2025, data cutoff, median progression-free and overall survival had not yet been reached. Estimated six-month progression-free survival was 84%, and estimated six-month overall survival was 90%. The most common grade 3 or higher treatment-related side effects were anemia, low neutrophil counts, and fatigue.
Those numbers are encouraging but early. Forty patients is a small group; response rates can shift with longer follow-up, and without a randomized control group, it is impossible to say how much of the benefit came from daraxonrasib rather than chemotherapy or from the way patients were selected.
Newly diagnosed patients may wonder whether to wait for the combination. Delaying standard treatment while hoping for access to an unapproved option carries its own risks, so that decision belongs in a conversation with the oncology team.
A Larger Trial Will Decide the First-Line Question
The answer should come from RASolute 303, a global phase 3 trial designed to enroll about 900 people with untreated metastatic pancreatic adenocarcinoma, regardless of their tumor's RAS mutation status. It compares daraxonrasib alone, daraxonrasib plus gemcitabine and nab-paclitaxel, and chemotherapy alone. Its primary goals are progression-free survival and overall survival. Because the 40-patient study enrolled only people whose tumors carried RAS mutations, the larger trial will also show whether any benefit extends to patients without such a mutation.
The mutated protein daraxonrasib targets fuels tumor growth in more than 90% of pancreatic cancers, and the American Cancer Society estimates about 67,000 new U.S. cases this year, the Associated Press reported. That is why moving an effective RAS inhibitor earlier in treatment could matter to many patients.
Oncologists have been enthusiastic about the drug's earlier results. Dr. Jeremy Jacox, a gastrointestinal medical oncologist at Yale School of Medicine, described the survival benefit seen in previously treated patients as "arguably the biggest, most important advance in the last 13 to 15 years in pancreatic cancer," WebMD reported. His comment addressed the single-drug results, not the combination now under study.
No timeline for RASolute 303 results accompanied the announcement. Patients interested in first-line access can ask their oncologist about eligibility and check the trial's ClinicalTrials.gov listing for participating sites.
Cost, Access, and Side Effects Patients Are Asking About
Revolution Medicines set Rasonque's price at about $39,800 for a one-month supply, according to the AP. Insurance coverage generally follows FDA-approved uses, so first-line use outside a trial may be harder to get covered. Patients can ask about manufacturer assistance programs and their plan's prior authorization rules. Those considering the trial can ask study coordinators which costs are covered and whether travel support is available.
The approved label carries warnings for skin reactions, mouth sores, diarrhea, gastrointestinal perforation, lung inflammation, and harm to a developing fetus. In pancreatic cancer trials, skin toxicity occurred in 86% of patients who took the drug, and the label reports 10% as grade 3, a severe level. New cough, shortness of breath, severe abdominal pain, or persistent diarrhea should be reported to the care team right away.
Patients should not stop or change current treatment based on this news. The designation signals FDA interest in a promising approach, but the combination's safety and effectiveness for untreated disease have not been established.
MedicalDaily will follow RASolute 303 and any future FDA filing for first-line use.
Key Questions Answered
What did the FDA grant?
The FDA granted Breakthrough Therapy designation to daraxonrasib combined with gemcitabine and nab-paclitaxel for previously untreated metastatic pancreatic cancer. Revolution Medicines announced it on Sept. 14.
Is daraxonrasib approved as a first treatment?
No, the first-line combination remains investigational. The drug is approved only for adults who have received at least one prior systemic therapy or who are not candidates for multiagent treatment.
What evidence supported the designation?
It was based on an early-stage study of 40 patients, in which the combination produced a confirmed response rate of 58%. The study had no comparison group, so larger trial results are still needed.
Who can get daraxonrasib now?
Adults with metastatic pancreatic adenocarcinoma who fit the approved label can receive it with a prescription. Untreated patients may be able to receive the combination through the RASolute 303 trial.
How much does daraxonrasib cost?
The company set the price at about $39,800 for a one-month supply, according to the Associated Press. Patients can ask about insurance coverage and manufacturer assistance programs.
What side effects are most common?
Skin reactions, mouth sores, and diarrhea are among the problems listed in the label's warnings. Lung inflammation and gastrointestinal perforation are less common but serious risks.
